mRNA And Oncology Pipeline Will Boost Markets But Face Delays

Published
09 Feb 25
Updated
06 Aug 25
AnalystConsensusTarget's Fair Value
US$136.65
18.3% undervalued intrinsic discount
06 Aug
US$111.66
Loading
1Y
38.5%
7D
1.5%

Author's Valuation

US$136.6

18.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 1.87%

Shared on30 Apr 25
Fair value Decreased 0.20%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on23 Apr 25
Fair value Decreased 1.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 2.26%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.

Shared on09 Apr 25
Fair value Increased 4.41%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 0.74%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.56%

AnalystConsensusTarget has decreased revenue growth from -4.7% to -5.2%.

Shared on19 Mar 25
Fair value Increased 3.49%

AnalystConsensusTarget has decreased revenue growth from -4.1% to -4.7%, increased profit margin from 15.8% to 19.6% and decreased future PE multiple from 93.1x to 80.2x.

Shared on10 Mar 25
Fair value Decreased 2.32%

AnalystConsensusTarget has increased revenue growth from -4.7% to -4.1%, increased profit margin from 10.5% to 15.8%, decreased future PE multiple from 140.4x to 93.1x and decreased shares outstanding growth rate from 0.0% to 0.0%.